This is expected as anti-IGF-1R therapy disrupts the negative feedback loop at the hypothalamic–pituitary axis, leading to elevated circulating growth hormone which can upregulate IGF-1R expression and other downstream pathways that sustain tumor growth (45). Here, GH1 is linked to neoplasm.